An investigation of the H1-receptor antagonist triprolidine: pharmacokinetics and antihistaminic effects.
A single oral dose of triprolidine hydrochloride, 0.04 mg/kg (mean dose 2.7 +/- SD 0.4 mg) was administered to seven healthy, fasting adult volunteers who had never been treated previously with H1-receptor antagonists. Blood sampling and intradermal tests with 0.01 ml of histamine phosphate (0.1 mg/ml) were performed at -0.25, 1, 2, 3, 4, 5, 6, 7, 8, and 12 hours after the dose. Wheal-and-flare circumferences were traced, and the areas were measured by planimetry. Pruritus was quantitated by use of a clinical score. Urine was collected in 6-hour pooled aliquots for a total of 24 hours. Serum and urine triprolidine concentrations were measured by high-performance liquid chromatography. Wheal-and-flare areas and pruritus decreased after the triprolidine dose. Suppression of mean flare size was statistically significant at 2, 3, 6 and 8 hours. Suppression of mean wheal size was not statistically significant at any time compared to predose values. The mean triprolidine serum half-life was 2.1 +/- 0.8 hours. The mean peak serum triprolidine concentration of 15.4 +/- 8.3 ng/ml occurred 2 hours after ingestion. No triprolidine was detected in the serum after 12 hours. The mean urinary excretion of unchanged triprolidine during 24 hours was 1.3 +/- 1.0% of the dose administered.
D000328:Adult; D002851:Chromatography, High Pressure Liquid; D006207:Half-Life; D006632:Histamine / Q000494:pharmacology; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000209:etiology; D007700:Kinetics; D011725:Pyridines / Q000378:metabolism*; D012882:Skin Tests; D014311:Triprolidine / Q000009:adverse effects / Q000097:blood / Q000378:metabolism* / Q000652:urine
D011725:Pyridines; D014311:Triprolidine; D006632:Histamine